A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital, Beijing

Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing

Beijing Tsinghua Changgung Hospital, Beijing

The First Hospital of China Medical University, Shenyang

Liaoning Cancer Hospital & Institute, Shenyang

The First Hospital of Jilin University, Changchun

Yanbian University Hospital, Yanji

Affiliated Tumor Hospital of Harbin Medical University, Harbin

Nantong Tumor Hospital, Nantong

The Fourth Affiliated Hospital of Anhui Medical University, Hefei

Qilu Hospital of Shandong University, Jinan

Tianjin Cancer Hospital, Tianjin

Zhejiang Cancer Hospital, Hangzhou

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Chongqing Cancer Hospital, Chongqing

The First Affilited Hospital of Chongqing Medical University, Chongqing

Hunan Cancer Hospital, Changsha

Zhongnan Hospital of Wuhan University, Wuhan

AnYang Tumor Hospital, Anyang

Guangdong Provincial People's Hospital, Guangzhou

Guangxi Medical University Affiliated Tumor Hospital, Nanning

The First Affiliated Hospital of Guangxi Medical University, Nanning

The Second People's Hospital of Neijiang, Neijiang

The Second Affiliated Hospital of PLA Airforce Military Medical University, Xi’an

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Shanxi Provincial People's Hospital, Xi’an

Xinjiang Uiger Municipal People's Hospital, Ürümqi

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

The fourth Hospital of Hebei Medical University, Shijiazhuang

Shanxi Cancer Hospital, Taiyuan